Simvastatin

辛伐他汀

Report date: 2026/03/19 20:00:18
NME

Base Information

Drug NameSimvastatin
Drug Alias NameSimvastatinum斯伐他汀辛伐他丁Szimvasztatin辛伐他汀钠 +[31] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHMG-CoA reductase inhibitors
TargetsHMG-CoA reductase
Therapy Area/IndicationsHeterozygous familial hypercholesterolemiaRejection of organ transplantationRejection of renal transplantation +[78] 
Global Approved IndicationsHomozygous familial hypercholesterolemiaHypertriglyceridemiaHypercholesterolemia +[9] 
Approved Indications in ChinaHypercholesterolemiaHyperlipoproteinemia Type VCoronary Disease +[4] 
Original Approved Country/TerritoryN/A
Original Approved Date1988/01/01
Country/TerritoryCanadaUnited StatesSweden +[24] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesOrganonSalerno Pharmaceuticals LLCINTERNATIONAL BIO SERVICES CO LTD +[19] 
Inactive CompaniesHanmi Pharmaceutical Co LtdUtah State UniversityDana-Farber Cancer Institute +[45] 
Active IndicationsHeterozygous familial hypercholesterolemiaHomozygous familial hypercholesterolemiaDepressive Disorder, Major +[32] 
Inactive IndicationsRejection of organ transplantationRejection of renal transplantationCoronavirus Disease 2019 (COVID-19) +[46] 

Other Information

ATC CodeC10AA01
Related LinksWikipediaDrugBankKEGG